Absci vs Cartesian Therapeutics
Absci and Cartesian Therapeutics are similar in size: $2.8m and $2.8m of revenue in their latest fiscal years. Absci grew faster (-38.2% against -92.8%). Absci kept more of each dollar of sales as profit: a net margin of -4113.7% against -4658.6%.
| Latest fiscal year | AbsciABSI, 2025 | Cartesian TherapeuticsRNAC, 2025 |
|---|---|---|
| Revenue | $2.8m | $2.8m |
| Revenue growth | -38.2% | -92.8% |
| Net income | −$115m | −$130m |
| Operating margin | -4297.0% | -5127.1% |
| Net margin | -4113.7% | -4658.6% |
| Return on equity | -62.5% | — |
| Free cash flow | −$94.0m | −$79.4m |
| Cash | $20.0m | $125m |
| Total debt | $873,000 | $0 |
| Debt to equity | 0.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 140 | 75 |
| Market value | $1.57bn | $193m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 5 buys, 2 sales | 1 buys, 3 sales |